{"id":"NCT03088813","sponsor":"Ipsen","briefTitle":"Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer","officialTitle":"RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-25","primaryCompletion":"2022-02-08","completion":"2023-07-27","firstPosted":"2017-03-23","resultsPosted":"2023-10-17","lastUpdate":"2025-02-19"},"enrollment":491,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Irinotecan liposome injection","otherNames":["ONIVYDE®"]},{"type":"DRUG","name":"Topotecan","otherNames":[]}],"arms":[{"label":"Part 1: Experimental Arm, dose level 1","type":"EXPERIMENTAL"},{"label":"Part 1: Experimental Arm, dose level 2","type":"EXPERIMENTAL"},{"label":"Part 2: Experimental Arm","type":"EXPERIMENTAL"},{"label":"Part 2: Control Arm","type":"ACTIVE_COMPARATOR"}],"summary":"A randomized, open label phase 3 study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy\n\nThe study was conducted in two parts:\n\n1. Dose determination of irinotecan liposome injection\n2. A randomized, efficacy study of irinotecan liposome injection versus topotecan","primaryOutcome":{"measure":"Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)","timeFrame":"The TEAEs were reported from the time of first study treatment administration (Day 1) up to 30 days after the date of last study treatment administration, approximately 680 days","effectByArm":[{"arm":"Part 1: Irinotecan Liposome Injection 85 mg/m^2","deltaMin":5,"sd":null},{"arm":"Part 1: Irinotecan Liposome Injection 70 mg/m^2","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":14},"locations":{"siteCount":118,"countries":["United States","Australia","Belgium","Brazil","China","France","Germany","Hungary","Italy","Poland","Romania","Russia","Serbia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["38648575","35195913"],"seeAlso":["https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2024/11/08172330/MM-398-01-03-04-lay-results-summary.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":5},"commonTop":["Anaemia","Diarrhoea","Neutropenia","Nausea","Thrombocytopenia"]}}